Silexion Therapeutics Corp receives Nasdaq delisting notice

Silexion Therapeutics Corp has filed an 8-K disclosing a notice from Nasdaq regarding failure to satisfy continued listing requirements. The filing indicates a potential delisting risk, though specific compliance deficiencies were not detailed in the summary. This development signals significant financial or operational distress for the issuer.